Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.

ABSTRACT:

Aim

To assess the efficacy and safety of add-on therapy with the dipeptidyl peptidase-4 inhibitor teneligliptin compared with sitagliptin in patients with type 2 diabetes (T2DM) inadequately controlled with metformin and glimepiride.

Materials and methods

This was a phase 3, randomized, double-blind, non-inferiority study of adult Korean subjects with T2DM (n = 201), with HbA1c ranging from 7.0% to 11.0%, on stable doses of metformin plus glimepiride. Subjects were randomized in a 1:1 fashion to receive either oral teneligliptin 20 mg or sitagliptin 100 mg for 24 weeks. The primary endpoint was change from baseline in HbA1c.

Results

At baseline, mean age was 60.56 ± 9.41 years, body mass index was 25.23 ± 2.85 kg/m² and HbA1c was 8.11% ± 0.79%. At 24 weeks,

SUBMITTER: Kim Y 

PROVIDER: S-EPMC6587707 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature